Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND ERBB3, c-erbB3, 2065, P21860, p180-ErbB3, c-erbB-3, ErbB-3, MDA-BF-1, HER3, p85-sErbB3, MGC88033, p45-sErbB3, ENSG00000065361, erbB3-S AND Treatment
108 results:

  • 1. DB-1310, an ADC comprised of a novel anti-her3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of her3-positive solid tumors.
    Li X; Yao J; Qu C; Luo L; Li B; Zhang Y; Zhu Z; Qiu Y; Hua H
    J Transl Med; 2024 Apr; 22(1):362. PubMed ID: 38632563
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Site specific genetic differences in colorectal cancer via Next-Generation-Sequencing using a multigene panel.
    Rencuzogullari A; Bisgin A; Erdogan KE; Gumus S; Yalav O; Boga I; Sonmezler O; Eray IC
    Ann Ital Chir; 2023; 94():605-611. PubMed ID: 38131395
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Endorobotic submucosal dissection of rectal lesions using the single port robot DaVinci-SP: initial experience of the first 10 cases.
    Ozgur I; Cheong JY; Liska D; Holubar S; Valante MA; Steele SR; Gorgun E
    ANZ J Surg; 2024 Apr; 94(4):691-696. PubMed ID: 38012087
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.
    Lu X; Li Y; Li Y; Zhang X; Shi J; Feng H; Yu Z; Gao Y
    BMC Cancer; 2023 Nov; 23(1):1117. PubMed ID: 37974093
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Pictilisib-Induced Resistance Is Mediated through FOXO1-Dependent Activation of Receptor Tyrosine Kinases in Mucinous colorectal Adenocarcinoma Cells.
    Kuracha MR; Govindarajan V; Loggie BW; Tobi M; McVicker BL
    Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569713
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Disparities in geospatial patterns of cancer care within urban counties and structural inequities in access to oncology care.
    McGee-Avila JK; Richmond J; Henry KA; Stroup AM; Tsui J
    Health Serv Res; 2023 Aug; 58 Suppl 2(Suppl 2):152-164. PubMed ID: 37208901
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. MicroRNA 483-3p overexpression unleashes invasive growth of metastatic colorectal cancer via NDRG1 downregulation and ensuing activation of the erbb3/AKT axis.
    Candiello E; Reato G; Verginelli F; Gambardella G; D Ambrosio A; Calandra N; Orzan F; Iuliano A; Albano R; Sassi F; Luraghi P; Comoglio PM; Bertotti A; Trusolino L; Boccaccio C
    Mol Oncol; 2023 Jul; 17(7):1280-1301. PubMed ID: 36862005
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Yap governs a lineage-specific neuregulin1 pathway-driven adaptive resistance to RAF kinase inhibitors.
    Garcia-Rendueles MER; Krishnamoorthy G; Saqcena M; Acuña-Ruiz A; Revilla G; de Stanchina E; Knauf JA; Lester R; Xu B; Ghossein RA; Fagin JA
    Mol Cancer; 2022 Dec; 21(1):213. PubMed ID: 36476495
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and erbb3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancer.
    Propper DJ; Gao F; Saunders MP; Sarker D; Hartley JA; Spanswick VJ; Lowe HL; Hackett LD; Ng TT; Barber PR; Weitsman GE; Pearce S; White L; Lopes A; Forsyth S; Hochhauser D
    Br J Cancer; 2023 Jan; 128(2):245-254. PubMed ID: 36352028
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Pertuzumab Plus Trastuzumab in Patients With colorectal cancer With
    Gupta R; Meric-Bernstam F; Rothe M; Garrett-Mayer E; Mangat PK; D'Andre S; Ahn ER; O'Lone R; Halabi S; Grantham GN; Schilsky RL
    JCO Precis Oncol; 2022 Oct; 6():e2200306. PubMed ID: 36315917
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. The HER family as therapeutic targets in colorectal cancer.
    Ye P; Wang Y; Li R; Chen W; Wan L; Cai P
    Crit Rev Oncol Hematol; 2022 Jun; 174():103681. PubMed ID: 35462030
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. MiR-323a regulates erbb3/EGFR and blocks gefitinib resistance acquisition in colorectal cancer.
    Zhang Y; Liang S; Xiao B; Hu J; Pang Y; Liu Y; Yang J; Ao J; Wei L; Luo X
    Cell Death Dis; 2022 Mar; 13(3):256. PubMed ID: 35319011
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Mechanisms of GZ17-6.02 resistance.
    Booth L; West C; Von Hoff D; Dent P
    Anticancer Drugs; 2022 Jun; 33(5):415-423. PubMed ID: 35276694
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Triple Targeting of HER Receptors Overcomes Heregulin-mediated Resistance to EGFR Blockade in colorectal cancer.
    Rau A; Janssen N; Kühl L; Sell T; Kalmykova S; Mürdter TE; Dahlke MH; Sers C; Morkel M; Schwab M; Kontermann RE; Olayioye MA
    Mol Cancer Ther; 2022 May; 21(5):799-809. PubMed ID: 35247930
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Diagnosis and treatment of ERBB2-Positive Metastatic colorectal cancer: A Review.
    Strickler JH; Yoshino T; Graham RP; Siena S; Bekaii-Saab T
    JAMA Oncol; 2022 May; 8(5):760-769. PubMed ID: 35238866
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignancies.
    Berlin J; Tolcher AW; Ding C; Whisenant JG; Horak ID; Wood DL; Nadler PI; Hansen UH; Lantto J; Skartved NJØ; Pedersen MW; Patnaik A
    Invest New Drugs; 2022 Jun; 40(3):586-595. PubMed ID: 35113285
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Anti‑her3 monoclonal antibody exerts antitumor activity in a mouse model of colorectal adenocarcinoma.
    Asano T; Ohishi T; Takei J; Nakamura T; Nanamiya R; Hosono H; Tanaka T; Sano M; Harada H; Kawada M; Kaneko MK; Kato Y
    Oncol Rep; 2021 Aug; 46(2):. PubMed ID: 34184091
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Effect of Cetuximab-Conjugated Gold Nanoparticles on the Cytotoxicity and Phenotypic Evolution of colorectal cancer Cells.
    El Hallal R; Lyu N; Wang Y
    Molecules; 2021 Jan; 26(3):. PubMed ID: 33499047
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell-like phenotype.
    Lupo B; Sassi F; Pinnelli M; Galimi F; Zanella ER; Vurchio V; Migliardi G; Gagliardi PA; Puliafito A; Manganaro D; Luraghi P; Kragh M; Pedersen MW; Horak ID; Boccaccio C; Medico E; Primo L; Nichol D; Spiteri I; Heide T; Vatsiou A; Graham TA; Élez E; Argiles G; Nuciforo P; Sottoriva A; Dienstmann R; Pasini D; Grassi E; Isella C; Bertotti A; Trusolino L
    Sci Transl Med; 2020 Aug; 12(555):. PubMed ID: 32759276
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Systems analysis of protein signatures predicting cetuximab responses in KRAS, NRAS, BRAF and PIK3CA wild-type patient-derived xenograft models of metastatic colorectal cancer.
    Lindner AU; Carberry S; Monsefi N; Barat A; Salvucci M; O'Byrne R; Zanella ER; Cremona M; Hennessy BT; Bertotti A; Trusolino L; Prehn JHM
    Int J Cancer; 2020 Nov; 147(10):2891-2901. PubMed ID: 32700762
    [TBL] [Abstract] [Full Text] [Related]  


    of 6.